Roche plans in 2013 to start three t-dm1 trials in early stage her2+ BC, they are:
As single-agent therapy for patients with residual invasive disease following preoperative (neoadjuvant) systemic treatment.
Used in combination with chemotherapy and pertuzumab in the adjuvant setting.
Used in combination with chemotherapy and pertuzumab in the neoadjuvant setting.
http://investor.immunogen.com/common...VU3S1&mobileid=#